In PDX models of colorectal and thyroid cancers, we observed significant inhibitory effect of the combination of selumetinib and KRT-232 on tumor growth across a spectrum of MAPK genomic backgrounds, including BRAF, KRAS, and NRAS mutations, compared to single-agent treatment with either drug. Here, KRAS is linked to thyroid cancer.